摘要
甲状腺未分化癌占甲状腺癌的1%-2%,死亡率高。就诊时肿瘤常已周围侵犯或远处转移而难以手术,R0/R1手术可以提高生存率。IMRT放疗技术可以提高放疗剂量并保护正常组织。目前无标准化疗方案,放化疗联合应用可以延长部分患者生存。靶向治疗将成为未来研究的方向。深入精确分析ATC基因组、优化组合靶向治疗方法可以形成个体化精准医疗来提高生存。现对甲状腺未分化癌治疗策略作一综述。
Anaplastic thyroid carcinomas（ATC） had a high mortality rate. It accounted for 1% - 2% of all thyroid cancers. Surrounding invasion or distant metastasis was often found at the initial diagnosis of ATC patients, and thus made it difficult for the surgery treatment. Relatively, R0 / R1 surgery could relatively improve the survival rate. IMRT method could both increase the radiotherapy dose and simultaneously protect normal tissues. Currently, there was no standard chemotherapy. The combination of radiotherapy and chemotherapy can prolong the survival time of some patients. Targeted therapy will become a hot research project in the future. Individual precise medical treatment will improve the survival by making in depth genomic analyses and optimizing combinatorial targeted therapy approaches for patients with ATC. In this article, we reviewed the treatment strategies for ATC patients.
出处
《肿瘤药学》
CAS
2015年第4期251-255,共5页
Anti-Tumor Pharmacy
关键词
甲状腺未分化癌
手术
放疗
化疗
靶向治疗
Anaplastic thyroid carcinomas
Surgery
Radiotherapy
Chemotherapy
Targeted therapy
